Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0739 +/- Pembrolizumab in NY-ESO-1+ Solid Tumors
NCT04939701Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Other Engineered Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ASP0739 in synovial sarcoma (SS), myxoid liposarcoma (MLPS), myxoid/round cell liposarcoma (MRCLS), ovarian cancer, non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Started Dec 2021; status: terminated.
02
Drugs
ASP0739
03
Conditions
synovial sarcoma (SS)myxoid liposarcoma (MLPS)myxoid/round cell liposarcoma (MRCLS)ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04939701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939701.